| Target Price | $66.30 |
| Price | $31.25 |
| Potential |
112.16%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Neoleukin Therapeutics Inc 2027 .
The average Neoleukin Therapeutics Inc target price is $66.30.
This is
112.16%
register free of charge
$174.30
457.76%
register free of charge
$46.46
48.67%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Neoleukin Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Neoleukin Therapeutics Inc stock has an average upside potential 2027 of
112.16%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 06 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 27 2026 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Jan 26 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 06 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 27 2026 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Jan 26 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


